Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications.

Biljana TubicVanda Marković-PekovićSaša JungićEleonora AllocatiBrian B Godman

Published in: Medicine access @ point of care (2021)

The limited use of mAbs including biosimilars needs to be addressed in B&H to improve the future care of patients within finite resources. We will monitor these developments.

Keyphrases

end stage renal disease
ejection fraction
healthcare
newly diagnosed
chronic kidney disease
palliative care
peritoneal dialysis
prognostic factors